Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Friday, April 29, 2016

#Investorideas Updates Global #Stock Directories; Additions Include #Biotech & #LifeSciences Stocks

#Investorideas Updates Global #Stock Directories; Additions Include #Biotech & #LifeSciences Stocks

(OTC:ENVD), (OTC:IMUN), (OTC:MDIT), (OCT:NAOV), (OTC:RXMD) and (OTC:PRGB) Added

Point Roberts, WA, Delta BC – April 29, 2016 – Investorideas.com, a global news source and investor resource covering leading sectors announces this week’s additions to its global stock directories include biotech & life sciences stocks.

Companies added include: Endonovo Therapeutics, Inc. (OTC: ENDV), Immune Therapeutics, Inc. (OTC: IMUN), Medite Cancer Diagnostics, Inc. (OTC: MDIT), NanoVibronix Inc. (OTC: NAOV), Progressive Care, Inc. (OTC: RXMD) and Protea Biosciences Group, Inc. (OTC: PRGB).

The newly added companies were participants in the recent SeeThru Equity & Brewer Group 2ndAnnual Innovations and Investor Conference held this past February.


About Investorideas.com - Big Ideas for Global Investors
InvestorIdeas.com is a digital news source and investor resource covering leading sectors including biotech and life sciences.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Thursday, April 28, 2016

Q BioMed Inc (OTCQB: $QBIO) CEO Pens Management Piece Featured in Life Science Leader

Q BioMed Inc (OTCQB: $QBIO) CEO Pens Management Piece Featured in Life Science Leader


NEW YORK - April 28, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology acceleration company reports the Company's CEO was featured in an article he wrote on venture capital titled Accelerators Enter When VCs Fear To Tread:

Life Science Leader magazine is an essential business journal for life science executives who work for everything from emerging biotechs to Big Pharmas. Their content is designed to inform readers of industry best practices and motivate them to implement those practices in their businesses.

Each month, Life Science Leader features interviews with executives from the leading pharma and biotech companies, including Pfizer, Merck, Daiichi Sankyo, Genentech, Genzyme, Eli Lilly, and Janssen, as well as the FDA and more. This exclusive thought leadership provides an in-depth look into industry trends and hot topics that will impact the growth of the pharma and biopharma markets. As the market is continually growing and innovating, these insights provide readers with actionable information and strategies to implement when navigating the evolving clinical, manufacturing, entrepreneurial, and regulatory landscapes.

Corin explains how times have changed for start-up biotechnology companies, though, and the challenges have grown in magnitude. These days, the very same venture capital firms that would hand out a few dollars in the early stages now are idling their time, investing much bigger sums only after much more development has occurred.

In the article, Corin leverages his expertise at Q BioMed Inc., where he focuses on acquiring licenses to innovative biomedical assets in the private company space or academic setting.
"Our team at Q Bio are dedicated to providing those developers with the strategic resources, developmental support, and expansion capital to ensure they meet their potential, with the ultimate goal of enabling them to provide products to patients in need. Our mission is to license and acquire innovative life sciences assets and accelerate their product development timelines to commercialize their drug candidates and devices or bring them to the next level in terms of valuation inflection and the attention of the larger Pharma players or IPO them as stand-alone companies or just grow a revenue model organically", states Corin.

Excerpt from the article:
"Most venture funds, for example, have become increasingly impatient to harvest returns from their investments, many expecting an 'exit' within only 2-4 years. This trend has been adverse for many biomedical technologies, since they generally have a much longer gestation cycle than communications, electronics or information technologies. In addition, many biomedical technologies require regulatory approvals, which further increases development costs and lengthens the investment cycle."

The one thing that really has not changed is the amount of equity the venture capitalists want when they finally do invest. For those who are only interested in getting their idea into the marketplace, giving up 80 or 90% of their company may be acceptable. Jonas Salk refused to patent his polio vaccine because his focus was preventing that disease and not making billions for himself. Handing off the headaches of running a business to people who studied accounting and marketing rather than organic chemistry and electrical engineering may be the solution for many researchers.

To read the entire article, please follow this link

About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.


Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435 

Visit this Company: http://www.qbiomed.com

More info on QBIO at Investorideas.com: http://www.investorideas.com/CO/QBIO/

Sign up for the free investor news and stock alerts:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.






Tuesday, April 26, 2016

Q BioMed Inc (OTCQB: $QBIO) to Present at the Global Chinese Financial Forum on April 30, 2016

Toronto, ON Conference Expects to Attract Over 200 Participants



NEW YORK - April 26, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology acceleration company, today announced that the company will present at the Global Chinese Financial Forum (GCFF). The GCFF is the most prominent series of bi-lingual financial functions in both North America and China. Established in 2000, GCFF's mandate is to provide a world-class platform connecting both the Asian and North American financial markets. GCFF assembles companies, financial institutions and investors who are interested in exploring new investment ideas and financial opportunities.

The conference is being held at the Marriott Courtyard Hotel in Markham, Ontario Canada at 7095 Woodbine Ave, Markham, Ontario.

The conference runs from 9am to 5pm. Q BioMed CEO, Denis Corin, will present at 10:20am.

Organizers expect the conference to attract over 200 participants consisting of pre-qualified investors, industry executives and professional service providers.

For more information or to register as an attendee of the conference, please click HERE.

To stay informed on Q BioMed developments please visit our website http://www.qbiomed.com and sign up for our news distribution.


About GCFF - GLOBAL CHINESE FINANCIAL FORUM
Organized by NAI Interactive, the Global Chinese Financial Forum (GCFF) is the most prominent series of bi-lingual financial functions in both North America and China. Established in 2000, GCFF's mandate is to provide a world-class platform connecting both the Asian and North American financial markets. We assemble companies, financial institutions and investors who are interested in exploring new investment ideas and financial opportunities.

With an extensive network covering both the North American and Chinese market alongside expertise in the global capital market, GCFF is supported by a strong foundation of financial resources. It enables GCFF to organize resourceful financial events that facilitate business growth and networks among financial institutions, public corporations, private companies, and investors of all levels.

In the past 16 years, over 35 GCFF conferences have been held in multiple locations worldwide including Vancouver, Toronto and China. The latest LNG Investment Conference was held in April 2014 to enlighten the Chinese community on the latest LNG development in British Columbia. The conference attracted over 200 participants consisting of pre-qualified investors, industry executives and professional service providers.

About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435 

Visit this Company: http://www.qbiomed.com

More info on QBIO at Investorideas.com: http://www.investorideas.com/CO/QBIO/

Sign up for the free investor news and stock alerts:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.




Gopher Protocol (OTCQB:$GOPH) to Expand Its Exclusive License IP Portfolio - New Patent for Guardian-LIFE Medical Patch, a Derivative of the Guardian Patch Technology

Gopher Protocol (OTCQB:$GOPH) to Expand Its Exclusive License IP Portfolio - New Patent for Guardian-LIFE Medical Patch, a Derivative of the Guardian Patch Technology


PERRIS, CA - April 26, 2016 (Investorideas.com Newswire) Gopher Protocol Inc. (OTCQB: GOPH) ("Gopher" and the "Company"), a development-stage Company developing a real-time, heuristic based, mobile technology, announced today that Dr. Rittman has applied for a patent for the Guardian-LIFE medical patch technology. If the patent is issued, Dr. Rittman will assign the patent to Guardian Patch LLC, the Company's technology licensing partner. The Guardian-LIFE medical patch is a derivative technology of GopherInsight™ microchip technology, which is currently licensed exclusively to the Company. The Guardian-LIFE technology is also to be licensed to the Company and such a license would represent a further expansion of the products licensed to the Company. The Guardian-LIFE technology represents a new sub-product of Guardian Patch LLC's Guardian Patch tracking technology.

The Guardian-LIFE technology is an electronic circuit within a sticky patch package is designed for human vital signs information detection and measurement. The Guardian-LIFE medical patch is based on an optical-acoustic laser technology. The medical patch detection and measurement device includes an affixed sensor system, an optical-acoustic sensing system, an analysis computerized system and a display unit. The user is intended to stick the patch against a human anatomical location for vital detection and measurements. The optical-acoustic system's data is analyzed by the computerized system to calculate and determine the human vital information and to present it on the display system. The system measures heart rate, a systolic blood pressure, a diastolic blood pressure, a mean arterial blood pressure, a pulse pressure and temperature.

The Guardian-LIFE electronic circuit embedded within the medical sticky patch includes a BIOS, ROM, RAM memory and at least one microprocessor or microcontroller. The electronic circuits are located within microchips or on the device's electronic board as separated microchips. The electronic circuit within the patch transmits the vital signs information via conventional network including Wi-Fi and Bluetooth. The system works in conjunction with a mobile software application to provide human vital detection and measurement functionalities within mobile devices and a web based application.

The Guardian Patch, the company's first exclusively licensed product to bring to the consumer markets, is a unique location technology that works with or without GPS. All of the technologies that are currently being developed by Guardian Patch LLC are currently based on GopherInsight™ microchip technology, which the Company exclusively holds a license to.


About Gopher Protocol Inc.
Gopher Protocol Inc. ("Gopher" and the "Company") (OTCQB: GOPH) (http://gopherprotocol.com/) is Development-stage Company that is developing a real-time, heuristic based, mobile technology, per license agreement it holds. Upon development, the technology will consist of a smart microchip, mobile application software and supporting software that run on a server. The system contemplates the creation of a global network, worldwide. Gopher believes this will be the first system that is developed using a human, heuristic based analysis engine. Since the core of the system will be its advanced microchip that will be able to be installed any mobile device, worldwide, Gopher expects that this will result in an internal, private network between all mobile devices utilizing the device by providing mobile technology for computing power enhancement, advanced mobile database management/sharing, and additional mobile features.

Corporate Site: http://gopherprotocol.com


Consumer and product website for Guardian Patch: http://www.guardianpatch.com/

Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact:
Dr. Dan Rittman, CTO
Gopher Protocol Inc.
888-685-7336

Visit this company: http://gopherprotocol.com/

More info on GOPH at Investorideas.com Visit: http://www.investorideas.com/CO/GOPH/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GOPH is a PR , social media and publishing client and compensates Investorideas.com ( three months effective April 4, 2016- three thousand five hundred per month )


Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Tuesday, April 12, 2016

Q BioMed (OTCQB: QBIO) News: Mannin Research to Present Glaucoma Therapeutics Treatment at MedCity INVEST Chicago

Q BioMed (OTCQB: QBIO) News: Mannin Research to Present Glaucoma Therapeutics Treatment at MedCity INVEST Chicago

Management to Present Lead drug candidate to Industry and Venture Finance Executives



NEW YORK - April 12, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology acceleration company is pleased to announce that its license technology partner, Mannin Research, will present at MATTER Midwest University HealthTech Showcase on April 12-13th, 2016. Mannin Research will present and discuss its glaucoma treatment technology at the forum to an audience of sophisticated healthcare investors.

The showcase is part of the opening reception for the MedCity INVEST conference. MedCity INVEST (formerly the MidAmerica Healthcare Venture Forum) is a national healthcare investing conference based in Chicago. MedCity INVEST is the premier national healthcare investing conference based in the Midwest, uniting active investors with corporate business development executives to facilitate investment opportunities with promising startups. For more than a decade, biotech, medical device, digital health, diagnostics, pharma and beyond have presented there to investors like AbbVie, Qualcomm Ventures, Mayo Clinic Ventures, Baxter, Baird, Venture Investors and beyond.

More than 300 industry leaders, venture capitalists and angel investors will be in attendance April 11-13 to discuss investment trends and interact with a number of promising early-stage start-up companies.

As part of their involvement with the Chicago-Canada Mentorship Program (C2MP), Mannin Research will be attending the MedCity INVEST conference. Mannin Research Inc. has also been selected to participate in the MATTER Midwest University HealthTech Showcase as part of the CIM@MATTER group of companies attending. MATTER is showcasing their top healthcare technologies at the official opening reception for the MedCity INVEST Conference. For more inforamtion on the event please visit their website

Mannin's CEO, Dr. George N. Nikopoulos stated, "We are looking forward to discussing Mannin's innovative solution for the treatment of glaucoma with industry leaders and investors at the Showcase on Monday and throughout the MedCity invest conference this week. This opportunity would not be possible without the C2MP and the CIM@MATTER program teams, and we thank them for their support."

Denis Corin, CEO of Q BioMed Inc. said, "This is a unique opportunity to present our innovative glaucoma therapeutic platform to pharma industry executives, venture capital funds and angel investors."

In October 2015 Q BioMed Inc entered into an agreement with Mannin Research to exclusively license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics. Mannin's primary focus is developing a first-in-class therapeutic eye-drop for glaucoma in adults and children, using a research platform designed to help develop new drugs for that indication and cystic kidney disease, among other diseases. Lead drug candidate MAN-01 is designed to treat abnormal vessels within the eye - thus treating glaucoma at its root causes.

We invite our shareholders and interested parties to subscribe to our email list and stay informed on our website at http://www.qbiomed.com and follow us on the social media feeds we use.


About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435 

Visit this Company: http://www.qbiomed.com

More info on QBIO at Investorideas.com: http://www.investorideas.com/CO/QBIO/

Sign up for the free investor news and stock alerts:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Thursday, April 7, 2016

Glaucoma Companies Aerie (Nasdaq:AERI), Glaukos (NYSE:GKOS), Q BioMed (OTCQB:QBIO), Inotek (Nasdaq:ITEK), NicOx SA (Paris: COX.PA) Approach a Devasting Disease with a Variety of Treatments

Glaucoma Companies Aerie (Nasdaq:AERI), Glaukos (NYSE:GKOS), Q BioMed (OTCQB:QBIO), Inotek (Nasdaq:ITEK), NicOx SA (Paris: COX.PA) Approach a Devasting Disease with  a Variety of Treatments

New York, NY; Pt, Roberts, WA - April 7, 2016- Investorideas.com, a digital global news source covering leading sectors including medical technology and biotech stocks releases the following report on Glaucoma and public companies currently involved in the treatment of the disease. Glaucoma is a group of eye diseases which result in damage to the eye’s optic nerve and left untreated will lead to vision loss and eventual blindness.

US Companies currently working on Glaucoma treatments include Q BioMed Inc, (QBIO), Aerie Pharmaceuticals (AERI), Glaukos Corporation (GKOS), Inotek (ITEK).

Internationally, NicOx SA (Paris: COX.PA) and Santen Pharmaceuticals Co. Ltd. (Tokyo:4536) are leading the way with research and development and treatment options for the disease.


Company News:
On March 28, Aerie Pharmaceuticals (NasdaqGM:AERI) issued a press release announcing the that dosing commenced of the first patients enrolled in Mercury 2, the Company’s second Phase 3 registration trial of Roclatan(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

The same day, Glaukos Corporation (NYSE:GKOS) announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its iStent® Trabecular Micro-Bypass Stent for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients diagnosed with mild to moderate open-angle glaucoma who are currently treated with ocular hypotensive medication. The iStent is the first-ever ab interno Micro-Invasive Glaucoma Surgery (MIGS) device approved for use in Japan.


Q BioMed Inc, (OTCQB:QBIO) expanded on the company’s Corporate Update with a Q&A with Investorideas.com and a video interview with StockNewsNow was also released.

In both interviews, President Denis Corin included the Mannin Research Inc. license agreement and the glaucoma eye drop treatment being developed by Dr. Susan Quaggin.  Mannin Research’s (Mannin) Glaucoma therapeutic is a first-in-class therapeutic designed to treat Primary Open-Angle Glaucoma. It is based on the research by Dr. Susan Quaggin, Director of the Feinberg Cardiovascular Research Institute and Chief of the Division of Nephrology and Hypertension at Northwestern University. The MAN-01 therapeutic is an important molecule in the context of new pharmaceuticals that can treat Glaucoma. Mannin’s therapeutic will address increased intraocular pressure in the eye by acting on a vessel in the eye called the Schlemm’s Canal, which is a main drainage path for the eye. Mannin is currently in the pre-clinical phase. Optimizing the molecule, the aim is to use it in the clinic in late 2017/early 2018.

In early March, Inotech Pharmaceutical Corporation (NasdaqGM: ITEK) announced that it had strengthened the Patent Estate for its lead drug candidate Trabodenoson, an investigational agent currently in pivotal Phase 3 clinical trials for the treatment of glaucoma.

In late February, NicOx SA (Paris: COX.PA) provided a corporate update which included a report on its US FDA review for an IOP (intraocular pressure) lowering singe-agent eye drop for patients with open-angle glaucoma

Santen Pharmaceuticals Co. Ltd. (Tokyo:4536.T; OTC: SNPHY) is focused on corneal disorders that lack effective treatment options and on glaucoma and retinal disorders that are increasing in prevalence due to the aging of society.

Novartis AG (NYSE:NVS) subsidiary Alcon, the global leader in eye care and a division of Novartis released news in February of 2016 announcing that it had entered into an agreement to acquire Transcend Medical, Inc., a privately-held, US-based company focused on developing minimally-invasive surgical devices to treat glaucoma.

Pfizer Inc’s (NYSE:PFE) Ophthalmology Unit indicates that it is interested in “establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers” in a number of ophthalmological areas including glaucoma.

Acadia Pharmaceuticals Inc.’s (NasdaqGS:ACAD) Muscarinic Program have discovered small-molecule product candidates for the treatment of glaucoma. Using a proprietary discovery platform, they identified a subtype of the muscarinic receptors that controls intraocular pressure and discovered lead compounds that selectively activate this target. 


The Market Outlook:
The global glaucoma surgical devices market is expected to reach USD 3.11 billion by 2020, growing at a CAGR of close to 41%, according to Technavio’s latest report.

TechNavio's analysts forecast the Global Glaucoma Therapeutics market will grow at a CAGR of 2.53 percent over the period 2013-2018.

TechNavio's analysts forecast the Global Glaucoma Devices market to grow at a CAGR of 20.72 percent over the period 2013-2018.




About Q BioMed Inc. (OTCQB:QBIO):
Q BioMed Inc. ("Q") is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

About Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI):
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma and ocular hypertension. It is expected that the NDA filing for Rhopressa (netarsudil ophthalmic solution) 0.02% will take place in the third quarter of 2016. The second product candidate, Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a Roclatan NDA filing is expected to take place in the second half of 2017. In addition, Aerie is further building its pipeline, including through research collaborations with GrayBug, Inc. and Ramot at Tel Aviv University.  http://www.aeriepharma.com/

About Glaukos (NYSE:GKOS):
Glaukos is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent® its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. http://www.glaukos.com/

About Inotek Pharmaceuticals Corp. (NasdaqGM:ITEK):
Inotek  is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development Trabodenoson was developed in Inotek's laboratories and is designed to restore the eye's natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. http://www.inotekpharma.com/

About NicOx SA (Paris: COX.PA):
NicOx is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight. Nicox's advanced pipeline features latanoprostene bunod for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and for which a New Drug Application (NDA) was submitted to the FDA by the Company's licensee Valeant. The Company's pipeline also features AC-170, a pre-NDA candidate for the treatment of ocular itching associated with allergic conjunctivitis, as well as two pre-MAA candidates in Europe: AzaSite® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery. Beyond these late-stage candidates, Nicox is developing a pipeline of next generation ophthalmology-focused candidates which utilize its proprietary nitric oxide (NO)-donating research platform. The Group has operations in Europe and the United States.
About Investorideas.com - Big Ideas for Global Investors
InvestorIdeas.com - digital media global news source, PR and social media in leading sectors.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for free news alerts at Investorideas.com
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411